CDT PRESS-RELEASE SEC Filing Analysis

Latest settled — T+20d

CDT ▼ -64.38% at T+20d

NEUTRAL call ✗ call lost -64.38% · α vs SPY -67.16% · entry $2.26 → $0.8050

Next anchor: T+60d in 7w

Currently $0.7420 · -67.17% from $2.26 entry

Entry anchored
May 5, 03:51 PM ET
via Databento tick

T+1d

-7.96%

call -7.96% · α -7.63%

$2.08

settled 5w ago

T+5d

-16.37%

call -16.37% · α -17.50%

$1.89

settled 28d ago

T+20d

-64.38%

call -64.38% · α -67.16%

$0.8050

settled 6d ago

T+60d

—

call — · α —

—

in 7w

Price Chart

Loading chart...

Executive Summary

CDT Equity announced that AZD5904, a myeloperoxidase inhibitor licensed from AstraZeneca, has entered the PCT phase for global IP protection. The asset has Phase 1 safety data in 181 subjects and is being positioned for out-licensing in idiopathic male infertility and oncology-associated infertility. This is a non-financial pipeline update with no revenue, earnings, or deal value disclosed.

Actionable Insight

This is a preclinical/early-stage pipeline update with no hard financial catalyst. Monitor for a definitive licensing agreement or partnership announcement, which would provide concrete deal value. Until then, the stock is likely to trade on sentiment and broader biotech sector dynamics.

Key Facts

AZD5904 entered the PCT phase for global patent protection
Asset originally licensed from AstraZeneca
181 subjects dosed across five Phase 1 studies with no drug-related adverse events
Target indications: idiopathic male infertility and oncology-associated infertility
Company is actively seeking out-licensing or strategic partnerships
No financial terms, deal value, or revenue disclosed

Financial Impact

No financial figures disclosed; potential future licensing revenue is speculative

Risk Factors

No guarantee of successful out-licensing or partnership
Asset is still in early clinical stage; regulatory and commercial risks remain
Company has a small market cap ($10M) and may face financing or Nasdaq listing challenges

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3288812

3 reports for CDT

T+1T+5T+20T+60

Track record builds as more directional reports settle.

Filters

Reports for CDT — sortable, filterable
	Type				Now
May 6, 2026 4w ago	Press Release NEUTRAL ★ 4/10	$2.26 $0.8050	▼ −64.38%	▼ −67.16%	$0.7420 (−67.17%)
Mar 4, 2026 13w ago	Press Release MIXED ★ 6/10	$17.70 $5.10	▼ −71.19%	▼ −66.77%	$0.7420 (−95.81%)
Feb 24, 2026 15w ago	8-K BULLISH ★ 7/10	$17.25 $10.88	▼ −36.96%	▼ −31.72%	$0.7420 (−95.70%)

US Market Status

Market Closed — Opens Thu (11h)

Related Tickers

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access